Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Affimed N.V is a biotechnology business based in the US. Affimed N-V shares (AFMD) are listed on the NASDAQ and all prices are listed in US Dollars. Affimed N-V employs 153 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$6.26|
|52-week range||$3.09 - $11.74|
|50-day moving average||$6.50|
|200-day moving average||$7.85|
|Wall St. target price||$14.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.43|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||-2.03%|
|1 month (2021-08-25)||-5.15%|
|3 months (2021-06-25)||-24.03%|
|6 months (2021-03-26)||-19.43%|
|1 year (2020-09-25)||87.99%|
|2 years (2019-09-25)||83.58%|
|3 years (2018-09-25)||36.09%|
|5 years (2016-09-23)||112.93%|
|Revenue TTM||$42.6 million|
|Gross profit TTM||$28.9 million|
|Return on assets TTM||-12.51%|
|Return on equity TTM||-39.9%|
|Market capitalisation||$765.1 million|
TTM: trailing 12 months
There are currently 4.2 million Affimed N-V shares held short by investors – that's known as Affimed N-V's "short interest". This figure is 13% up from 3.8 million last month.
There are a few different ways that this level of interest in shorting Affimed N-V shares can be evaluated.
Affimed N-V's "short interest ratio" (SIR) is the quantity of Affimed N-V shares currently shorted divided by the average quantity of Affimed N-V shares traded daily (recently around 1.1 million). Affimed N-V's SIR currently stands at 3.81. In other words for every 100,000 Affimed N-V shares traded daily on the market, roughly 3810 shares are currently held short.
However Affimed N-V's short interest can also be evaluated against the total number of Affimed N-V shares, or, against the total number of tradable Affimed N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Affimed N-V's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Affimed N-V shares in existence, roughly 40 shares are currently held short) or 0.0364% of the tradable shares (for every 100,000 tradable Affimed N-V shares, roughly 36 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Affimed N-V.
Find out more about how you can short Affimed N-V stock.
We're not expecting Affimed N-V to pay a dividend over the next 12 months.
Over the last 12 months, Affimed N-V's shares have ranged in value from as little as $3.085 up to $11.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Affimed N-V's is 2.6468. This would suggest that Affimed N-V's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Affimed N. V. , a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc. ; Roivant Sciences Ltd.
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 20, 2021
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.